Trial Profile
Phase 1 dose escalation study of sorafenib with palliative radiation therapy : The TAP study
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer; Liver cancer; Renal cell carcinoma; Thyroid cancer
- Focus Adverse reactions; Pharmacokinetics
- 13 Feb 2018 According to results published in the Radiotherapy and Oncology, trial was terminated early as slow accrual and sorafenib-related systemic toxicity prevented efficient evaluation of RT-related DLTs.
- 13 Feb 2018 New trial record